NEW YORK (360Dx) – Hamilton and Enable Biosciences announced on Thursday a collaboration to fully automate the processing of Enable's ultra-sensitive immunoassay technology in a hands-free workflow with Hamilton's automated workstation.
Leveraging Hamilton's Microlab Star workstation, the collaboration is aimed at automating the processing of up to 96 liquid biopsy samples at one time using Enable Bio's Antibody Detection by Agglutination PCR (ADAP) technology for immunoassays. The ADAP platform uses synthetic antigen-DNA conjugates to detect antibodies in liquid biopsy samples with a thousandfold to 10 thousandfold greater analytical sensitivity compared to other single and multiplex assay technologies, the partners said.
The ADAP technology is currently available for research applications in type 1 diabetes, Lyme disease, allergy, and HIV testing.
Hamilton's Microlab Star automated workstation is available preconfigured to work with the diabetes ADAP assay with additional chemistry workflows to follow shortly. By automating the ADAP assay workflow on the Microlab Star platform, sample throughput is increased "significantly," while active labor time, and risks of error and variability "are virtually eliminated compared to manual methods," Hamilton and Enable Bio said.
The Microlab Star system enabled for the ADAP assay technology will be copromoted by the partners.
Financial and other terms of the deal were not disclosed.
Based in Reno, Nevada; Franklin, Massachusetts; and Bonaduz, Switzerland, Hamilton provides automated liquid handling workstations and laboratory automation technologies for scientific applications. Enable Bio is headquartered in South San Francisco and develops multiplex immunoassays.